In vitro antimicrobial activity of meropenem againts clinical isolates of various bacterial species from pediatric patients in Japan

Japanese Journal of Chemotherapy

Volumn 52, Issue 1, 2004, Pages 1-16

  Kanazawa, Katsunori ^a   Ueda, Yutaka ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antimicrobial activity MIC; Child; Clinical isolates; Meropenem

Indexed keywords

AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; IMIPENEM; MEROPENEM; OXACILLIN; PANIPENEM;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; JAPAN; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA MENINGITIDIS; NONHUMAN; SPECIES DIVERSITY; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE;

EID: 1142287386     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Sunagawa M, Matsumura H, Sumita Y, et al.: Structural features resulting in convulsive activity of carbapenem compounds: Effect of C-2 side chain. J. Antibiot. 48: 408-416, 1995
2. Japanese source. Jpn. J. Antibiot. 49: 1-16, 1996
3. Japanese source. 51: 762-781, 2003
4. Japanese source. Jpn. J. Antibiot. 49: 175-193, 1996
5. Japanese source. Jpn. J. Antibiot. 54: 145-170, 2001
6. Japanese source. 48: 585-609, 2000
7. Japanese source. 48: 610-632, 2000
8. Japanese source. Jpn. J. Antibiot. 50: 683-703, 1997
9. Japanese source. 43: 12-26, 1995
10. Japanese source. 44: 595-609, 1996
11. Japanese source. 44: 610-625, 1996
12. Pitkin D H, Sheikh W, Nadler H L: Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 north american centers. Clin. Infect. Dis. 24 (Suppl. 2): S238-S248, 1997
13. Turner P J: MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview. J. Antimicrob. Chemother. 46 (Topic T2): 9-23, 2000
14. Fuchs P C, Barry A L, Brown S D: Comparative in vitro antimicrobial activity of a new carbapenem, E 1010, and tentative disk diffusion test interpretive criteria. J. Antimicrob. Chemother. 48: 23-28, 2001
15. Aldridge K E, Ashcraft D, Cambre K, et al.: Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob. Agents Chemother. 45: 1238-1243, 2001
16. Pfaller M A, Jones R N: MYSTIC (Meropenem Yearly Susceptibility Test Information Collection results from the Americas: resistance implications in the treatment of serious infections. J. Antimicrob. Chemother. 46 (Topic T 2): 25-37, 2000
17. Pfaller M A, Jones R N, Biedenbach D J: Antimicrobial resistance trends in medical centers using carbapenems: Report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41: 177-182, 2001
18. National Committee for Clinical Laboratory Standards (NCCLS): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard-fifth edition (M 7-A 5), NCCLS, Wayne, PA, 2001
19. National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testing; Eleventh informational supplement (M 100-S 11), NCCLS, Wayne, PA, 2001
20. National Committee for Clinical Laboratory Standards (NCCLS): Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard-fifth edition (M 11-A 5), NCCLS, Wayne, PA, 2001
21. Bradley J S, Faulkner K L, Klugman K P: Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr. Infect. Dis. J. 15: 749-757, 1996
22. Schuler D: Safety and efficacy of meropenem in hospitalised children: randomized comparison with cefotaxime, alone and combined with metronidazole or amikacin. J. Antimicrob. Chemother. 36 (Suppl. A): 99-108, 1995
23. Klugman K P, Dagan R: Rondomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob. Agents Chemother. 39: 1140-1146, 1995
24. Snedden S, Rudoy R, Arrieta A, et al.: Meropenem versus cefotaxime-based therapy for the initial treatment of infants and children hospitalised with non-CNS infections. Clin. Drug Invest. 17: 9-20, 1999
25. Odio C M, Puig J R, Feris J M, et al.: Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr. Infect. Dis. J. 18: 581-590, 1999
26. Principi N, Marchisio P: Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. J. Chemother. 10: 108-113, 1998
27. Japanese source. Jpn. J. Antibiot. 45: 697-717, 1992
28. Japanese source. 1993
29. Dagan R, Velghe L, Rodda J L, et al.: Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J. Antimicrob. Chemother. 34: 175-179, 1994
30. Japanese source. 50: 794-804, 2002
31. Japanese source. 51: 60-70, 2003
32. Japanese source. 80, 2003
33. Japanese source. 51 (S-A): 83, 2003
34. Japanese source. 51 (S-A): 83, 2003
35. Japanese source. 45: 757-761, 1997
36. Japanese source. 42: 905-914, 1994
37. Japanese source. 50: 161-170, 2002